"„ნიუ ჰოსპიტალსი“ ევროპული სტანდარტების დაცვით აშენებული, 285 საწოლიანი, მრავალპროფილური კლინიკაა, რომელიც 2011 წლიდან უმაღლესი ხარისხის სტაციონარულ და ამბულატორიულ სერვისებს სთავაზობს პაციენტებს."

During the past decade, New Hospitals conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New Hospitals" #1 sponsor was "EMD Serono Research & Development Institute, Inc." with 2 trials, followed by "Gilead Sciences" with 1 trials sponsored, "Incyte Biosciences International Sàrl" with 1 trials sponsored, "Incyte Corporation" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New Hospitals" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Everest Medicines" with 1 trials as a collaborator, "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator and "Zai Lab (Shanghai) Co., Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "New Hospitals" are "Head and Neck Cancer" (2 trials), "Esophagitis" (1 trials), "Locally Advanced or Metastatic Unresectable Urothelial Cancer" (1 trials), "Metastatic Nonsquamous Non-Small Cell Lung Cancer" (1 trials) and "Metastatic Squamous Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "New Hospitals" in a lesser frequency.

Most popular intervention types in "New Hospitals" are "Drug" (7 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Cisplatin" (2 trials), "Paclitaxel" (2 trials), "Retifanlimab" (2 trials) and "Xevinapant (Debio 1143)" (2 trials). Other intervention names were less common.

The vast majority of trials in "New Hospitals" are 7 trials for "All" genders.

Currently, there are NaN active trials in "New Hospitals". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in New Hospitals, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in New Hospitals, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".